💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Investor says Martin Shkreli reminded him of 'Rain Man'

Published 07/10/2017, 05:37 PM
Updated 07/10/2017, 05:40 PM
© Reuters. Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York

By Brendan Pierson

(Reuters) - An investor in Martin Shkreli's hedge fund testified on Monday that the former drug company executive, now on trial for securities fraud in federal court in New York, reminded him of Dustin Hoffman's autistic character in the movie "Rain Man."

Schuyler Marshall, chairman of the board of the real estate company Rosewood Corp, said under cross-examination by Shkreli's lawyer, Benjamin Brafman, that he was not claiming Shkreli was autistic.

"The reference here was that this was just an intensely focused, bright guy who knew his stuff," Marshall told jurors.

Hoffman's character in the 1988 film is an autistic savant with exceptional mental abilities but difficulty relating to other people.

Shkreli, 34, gained notoriety in 2015 when he raised the price of a life-saving drug by 5,000 percent as the chief executive officer of Turing Pharmaceuticals, sparking outrage among patients and U.S. lawmakers and earning him the nickname "pharma bro."

The charges he is on trial for stem not from his time at Turing, but from his management of hedge fund MSMB Capital Management, another fund called MSMB Healthcare and drug company Retrophin between 2009 and 2014. Prosecutors say he deceived investors in the funds and eventually repaid them with money stolen from Retrophin, which Shkreli founded in 2011 but was ousted from as CEO in 2014.

Marshall's testimony fit into the picture that Brafman painted in his fiery opening argument of Shkreli as a socially awkward "nerd" who was bullied and manipulated by others.

Like other investors who have testified in the trial, Marshall, who invested more than $200,000 in MSMB Capital, said that while Shkreli misled him about the fund's operations, he did not lose money.

At one point, Marshall testified, he even used the phrase "no harm, no foul" in a communication with Shkreli.

"He paid back my investment and then some," Marshall said.

© Reuters. Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York

The trial, now in its seventh day, is expected to last up to six weeks.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.